Size | Price | Stock | Qty |
---|---|---|---|
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
50g |
|
||
100g |
|
||
Other Sizes |
|
Purity: ≥98%
Nalidixic acid (formerly known as NSC-82174; NSC82174; Nevigramon, Neggram, Wintomylon, WIN 18,320), a synthetic 1,8-naphthyridine antimicrobial agent used to treat infections, is the first synthetic quinolone-based antibiotic with a narrow spectrum of bacteriocidal effects. It functions as an inhibitor of the bacterial DNA gyrase A subunit. With only a small amount of anti-gram-positive activity, nalidixic acid works best against gram-negative bacteria. It has bacteriostatic effects at lower concentrations and bactericidal effects at higher concentrations.
Targets |
Quinolone; Topoisomerase
|
---|---|
ln Vitro |
Nalidixic acid exhibits antimicrobial activity against a range of microorganisms, including Salmonella spp., Shigella spp., Brucella spp., Escherichia coli, Pasteurella spp., Klebsiella pneuiioniae, Aerobacter aeroyenes, Proteus spp., and 1.0-25.0 μg/ml. Its MIC values are 5.0-12.5 μg/ml, 0.5-2.5 μg/ml, 0.8-25.0 μg/ml, 1.25-30.0 μg/ml, 8-3.2 μg/ml, and 7.5-10.0 μg/ml, respectively[1].
|
ln Vivo |
Gram-negative bacteria are the target of nalidixic acid's greatest in vivo activity, whereas Gram-positive organisms are typically more resilient. The ED50 values of E. coli, A. aerobacter, Proteus mirabilis, and Shigella fkxneri, which cause systemic infections, are 25 mg/kg, 60 mg/kg, 50 mg/kg, and 62 mg/kg, respectively, indicating maximum activity[1].
Nalidixic acid's oral, intravenous, and subcutaneous doses of 3300 mg/kg, 176 mg/kg, and 500 mg/kg, respectively, are the acute toxicity (LD50) in mice after parenteral and oral administration[1]. |
References |
Molecular Formula |
C12H12N2O3
|
|
---|---|---|
Molecular Weight |
232.24
|
|
Exact Mass |
232.08
|
|
Elemental Analysis |
C, 62.06; H, 5.21; N, 12.06; O, 20.67
|
|
CAS # |
389-08-2
|
|
Appearance |
Solid powder
|
|
SMILES |
CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O
|
|
InChi Key |
MHWLWQUZZRMNGJ-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)
|
|
Chemical Name |
1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.3059 mL | 21.5295 mL | 43.0589 mL | |
5 mM | 0.8612 mL | 4.3059 mL | 8.6118 mL | |
10 mM | 0.4306 mL | 2.1529 mL | 4.3059 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.